search
Back to results

Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.

Primary Purpose

Positron-Emission Tomography, Lymph Node Metastases, Thyroid Cancer

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
<Sup>18<Sup>F-FDG PET/CT dynamic scan
B-ultrasonography
Sponsored by
Fifth Affiliated Hospital, Sun Yat-Sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Positron-Emission Tomography

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • • Accurately diagnosing primary papillary thyroid cancer according to pathological diagnostic criteria .

    • Thyroid papillary carcinoma was suspected by thyroid ultrasound text and/or neck CT.
    • The age is more than 18 years old and less than 65 years old. There is no gender restriction.
    • Untreated patients who have not received surgery, interventional therapy,chemotherapy, biotherapy, and radiation therapy.
    • Physical condition score of Eastern Cooperative Oncology Group(ECOG): 0-2; no major organ dysfunction; oxygen partial pressure ≥ 10.64 kilopascal(kPa); white blood cell count≥ 4 × 109/L; hemoglobin≥ 9.5g/dL; neutrophil absolute count ≥ 1.5 × 109 / L; platelet count ≥ 100× 109 / L; total bilirubin ≤ 1.5 times of the upper limit of normal value;creatinine ≤ 1.25 times of the upper limit of normal value; and creatinine clearance ≥ 60ml / min.
    • Be able to obtain complete follow-up information, understand the situation of this study and sign informed consent.

Exclusion Criteria:

  • • Poorly controlled diabetics (fasting blood glucose levels > 200 mg/dL).• In addition to four types of malignant tumors that can be treated with radical resection, such as cervical cancer in situ, basal or squamous cell skin cancer, (breast) ductal carcinoma in situ, and organ localized prostate cancer, suffering from any other malignant tumors within 5 years.• Breastfeeding and/or pregnant women.

    • Patients with severe bleeding tendencies (prothrombin time less than 50%,cannot be corrected by treatment with vitamin K, etc.).
    • Recent severe hemoptysis, severe cough, dyspnea or patients are not able to cooperate.
    • People with severe emphysema, pulmonary congestion, and pulmonary heart disease.
    • Researchers believe that the subject may not be able to complete this study or may not be able to comply with the requirements of this study (for management reasons or other reasons).

Sites / Locations

  • Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

<Sup>18<Sup>F-FDG PET/CT study group

B-ultrasonography group

Arm Description

<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.

B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.

Outcomes

Primary Outcome Measures

Number of lymph nodes dissected
Count the number of lymph nodes dissected during operation of every Participants.
Number of Participants diagnosed with lymph node metastasis by <Sup>18<Sup>F-FDG PET/CT dynamic scans.
Count the number of Participants diagnosed with lymph node metastasis by <Sup>18<Sup>F-FDG PET/CT dynamic scans.
Number of Participants diagnosed with lymph node metastasis by Postoperative pathology
Count the number of Participants diagnosed with lymph node metastasis by Postoperative pathology.
The number of lymph node metastases in patients with different Genetic types
To count the number of lymph node metastases in patients with different Genetic types basing on genetic testing.

Secondary Outcome Measures

Calculating the overall diagnostic sensitivity of <Sup>18<Sup>F-FDG PET/CT dynamic scans
Calculating the overall diagnostic sensitivity based on the results of <Sup>18<Sup>F-FDG PET/CT dynamic scans and Postoperative pathology.
Calculating the overall diagnostic specificity of <Sup>18<Sup>F-FDG PET/CT dynamic scans
Calculating the overall diagnostic specificity based on the results of <Sup>18<Sup>F-FDG PET/CT dynamic scans and Postoperative pathology.
Calculating the receiver operating characteristic curve(ROC)
Calculate receiver operating characteristic curve(ROC) based on sensitivity and specificity.
Calculating the radionics indicators of <Sup>18<Sup>F-FDG PET/CT
Based on the results above,to calculate the radionics indicators of <Sup>18<Sup>F-FDG PET/CT dynamic scans in detecting metastatic central lymph nodes in participants with papillary thyroid cancer .

Full Information

First Posted
December 17, 2018
Last Updated
July 27, 2022
Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
search

1. Study Identification

Unique Protocol Identification Number
NCT03830242
Brief Title
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
Official Title
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to make up for the gap by performing a dynamic scan of <Sup>18<Sup>F-FDG PET/CT on newly diagnosed patients with papillary thyroid carcinoma. Pathological and genomic studies are performed. The differences between metastatic central lymph nodes images and tissues are compared at the same time. <Sup>18<Sup>F-FDG PET/CT dynamic imaging is explored in metastatic central lymph nodes with papillary thyroid cancer for the diagnostic value.
Detailed Description
Thyroid cancer is the most common malignant tumor in human endocrine system, accounting for 0.2% ~ 1.0% of malignant tumors .According to the global cancer report released by the world health organization (WHO) in 2014, 50% of the new cases of thyroid cancer are papillary thyroid cancer (PTC). In recent years, the incidence of thyroid cancer in China shows an increasing trend, especially the composition ratio of thyroid micro-papillary carcinoma with the focal diameter <1 cm increases rapidly.Although PTC has a good prognosis, according to a Meta analysis , PTC lymph node metastasis rate is as high as 28.0%.The central lymph node is the most common metastatic site of papillary thyroid carcinoma.In addition, it has been reported in literature that lymph nodes in the central region are the first stop of thyroid papillary carcinoma metastasis (i.e., sentinel lymph nodes), and lymph nodes metastatic to this point are prone to infringe the peripheral esophagus, trachea and recurrent laryngeal nerve at an early stage.A large number of clinical cases have confirmed that lymph node metastasis of thyroid cancer significantly increases the local recurrence rate after surgery.More studies have shown that regional lymph node metastasis increases mortality.Therefore, the treatment of lymph node metastasis should not be ignored in PTC patients.However, at present, preoperative imaging has certain limitations in the judgment of lymph node metastasis in the central region : ultrasound has advantages in the judgment of lymph node metastasis in the peripheral group, but poor display in the central group.Although MRI scan of head and neck can be multi-directional and multi-sequence imaging, and the resolution of soft tissue is high, it is not good at showing calcification.Conventional CT alone based on lymph node morphology to determine metastasis also has some limitations;Positron emission tomography (PET) sensitivity was < 40%.Although one study showed that the probability of non-missed diagnosis of lymph nodes in central PTC region by thin slice CT scan was 100%, the specificity was low and the study was retrospective.Therefore, b-ultrasound, MRI, CT, PET and other auxiliary examinations have not been able to effectively detect all central metastatic lymph nodes before surgery.For management of cervical lymph nodes ,2015 American Thyroid Association(ATA) guidelines show that thyroid+therapeutic Ⅵ area lymph node dissection should be undertaken if in central or lateral lymph nodes are involved.Chinese guidelines recommend that, in order to avoid operative complications as far as possible (i.e. effective retainment of the parathyroid gland and recurrent laryngeal nerve), regardless of the size of the primary thyroid lesion, lymph node dissection in the central area on the same side of the lesion should be performed at least.However, in 2017, the second edition of National Comprehensive Cancer Network(NCCN) thyroid tumor guidelines believed that if lymph nodes in the central region were negative, preventive central region lymph node dissection was not recommended.Above all,there is so much controversy over lymph node dissection in the central region. Therefore,it is of great significance to effectively evaluate the preoperative lymph nodes station in the central region of thyroid papillary carcinoma. Early dynamic imaging examination of <Sup>18<Sup>F-FDG PET/CT can be defined as a imaging method to detect the status of radioactive tracer (<Sup>18<Sup>F-FDG) which travels with the blood flow and is continuously absorbed and excreted by organs (or diseased) tissues after being introduced into the body in the early stage.This development reflects the change of <Sup>18<Sup>F-FDG activity with time in the early stage of entering the body, and can provide information about the dynamic change of tracer metabolism and distribution in tissues with time, so that it can provide more metabolic and distribution details of tumor lesions and metastatic lesions than static scanning.At present, many studies have shown that <Sup>18<Sup>F-FDG PET/CT early dynamic imaging technology can effectively improve the sensitivity of hepatocellular carcinoma ,renal cell carcinoma and other tumors.More amazing,there may be more advantages in evaluating lymph node metastasis.The blood supply of lymph nodes metastatic of thyroid papillary carcinoma is abundant, which helps to locate the metastatic tumor lymph node.However,there is no relevant study.Now , investigators plan to observe the significance of the method to evaluate the central lymph node metastasis in thyroid papillary carcinoma as well as the intrinsic correlations between the significance and postoperative pathological results ,which may help to develop surgical strategy by preoperative evaluation and avoiding additional dissection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Positron-Emission Tomography, Lymph Node Metastases, Thyroid Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
<Sup>18<Sup>F-FDG PET/CT study group
Arm Type
Experimental
Arm Description
<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Arm Title
B-ultrasonography group
Arm Type
Other
Arm Description
B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Intervention Type
Diagnostic Test
Intervention Name(s)
<Sup>18<Sup>F-FDG PET/CT dynamic scan
Intervention Description
The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Intervention Type
Diagnostic Test
Intervention Name(s)
B-ultrasonography
Intervention Description
The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Primary Outcome Measure Information:
Title
Number of lymph nodes dissected
Description
Count the number of lymph nodes dissected during operation of every Participants.
Time Frame
12 months
Title
Number of Participants diagnosed with lymph node metastasis by <Sup>18<Sup>F-FDG PET/CT dynamic scans.
Description
Count the number of Participants diagnosed with lymph node metastasis by <Sup>18<Sup>F-FDG PET/CT dynamic scans.
Time Frame
12 months
Title
Number of Participants diagnosed with lymph node metastasis by Postoperative pathology
Description
Count the number of Participants diagnosed with lymph node metastasis by Postoperative pathology.
Time Frame
12 months
Title
The number of lymph node metastases in patients with different Genetic types
Description
To count the number of lymph node metastases in patients with different Genetic types basing on genetic testing.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Calculating the overall diagnostic sensitivity of <Sup>18<Sup>F-FDG PET/CT dynamic scans
Description
Calculating the overall diagnostic sensitivity based on the results of <Sup>18<Sup>F-FDG PET/CT dynamic scans and Postoperative pathology.
Time Frame
12 months
Title
Calculating the overall diagnostic specificity of <Sup>18<Sup>F-FDG PET/CT dynamic scans
Description
Calculating the overall diagnostic specificity based on the results of <Sup>18<Sup>F-FDG PET/CT dynamic scans and Postoperative pathology.
Time Frame
12 months
Title
Calculating the receiver operating characteristic curve(ROC)
Description
Calculate receiver operating characteristic curve(ROC) based on sensitivity and specificity.
Time Frame
12 months
Title
Calculating the radionics indicators of <Sup>18<Sup>F-FDG PET/CT
Description
Based on the results above,to calculate the radionics indicators of <Sup>18<Sup>F-FDG PET/CT dynamic scans in detecting metastatic central lymph nodes in participants with papillary thyroid cancer .
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Accurately diagnosing primary papillary thyroid cancer according to pathological diagnostic criteria . Thyroid papillary carcinoma was suspected by thyroid ultrasound text and/or neck CT. The age is more than 18 years old and less than 65 years old. There is no gender restriction. Untreated patients who have not received surgery, interventional therapy,chemotherapy, biotherapy, and radiation therapy. Physical condition score of Eastern Cooperative Oncology Group(ECOG): 0-2; no major organ dysfunction; oxygen partial pressure ≥ 10.64 kilopascal(kPa); white blood cell count≥ 4 × 109/L; hemoglobin≥ 9.5g/dL; neutrophil absolute count ≥ 1.5 × 109 / L; platelet count ≥ 100× 109 / L; total bilirubin ≤ 1.5 times of the upper limit of normal value;creatinine ≤ 1.25 times of the upper limit of normal value; and creatinine clearance ≥ 60ml / min. Be able to obtain complete follow-up information, understand the situation of this study and sign informed consent. Exclusion Criteria: • Poorly controlled diabetics (fasting blood glucose levels > 200 mg/dL).• In addition to four types of malignant tumors that can be treated with radical resection, such as cervical cancer in situ, basal or squamous cell skin cancer, (breast) ductal carcinoma in situ, and organ localized prostate cancer, suffering from any other malignant tumors within 5 years.• Breastfeeding and/or pregnant women. Patients with severe bleeding tendencies (prothrombin time less than 50%,cannot be corrected by treatment with vitamin K, etc.). Recent severe hemoptysis, severe cough, dyspnea or patients are not able to cooperate. People with severe emphysema, pulmonary congestion, and pulmonary heart disease. Researchers believe that the subject may not be able to complete this study or may not be able to comply with the requirements of this study (for management reasons or other reasons).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hongjun Jin, doctor
Phone
0756-2526136
Email
jinhj3@mail.sysu.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Qingan Zeng, master
Phone
0756-2528810
Email
1056555022@qq.com
Facility Information:
Facility Name
Fifth Affiliated Hospital, Sun Yat-Sen University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hongjun JIN, doctor
Phone
0756-2526136
Email
jinhj3@mail.sysu.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.

We'll reach out to this number within 24 hrs